Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Andrew Fedoriw(GlaxoSmithKline (United States)), Weiyi Peng(University of Houston)
Cited by 31
Related Papers
Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators
|Journal for ImmunoTherapy of Cancer|2021|47
MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors
|Journal for ImmunoTherapy of Cancer|2024|18
Single-cell CRISPR immune screens reveal immunological roles of tumor intrinsic factors
|NAR Cancer|2022|5
Tumor Intrinsic METTL5 Modulates ATF4 Translation to Prevent T Cell‐Induced Ferroptosis in Ovarian Cancer
|Advanced Science|2025|2
<i>LRRK2</i> G2019S mutation suppresses differentiation of Th9 and Treg cells via JAK/STAT3
|bioRxiv (Cold Spring Harbor Laboratory)|2024|1